Zhengzhou Seastar Banghe Biological Pharmaceutical Co., Ltd.

1) Evaluate the pharmacokinetic (PK) characteristics of human fibrinogen in patients with congenital fibrinogen deficiency or deficiency through a single-dose PK study; 2) Observe the efficacy and safety of human fibrinogen in treating patients with congenital fibrinogen deficiency or deficiency; 3) Evaluate the pharmacokinetic (PK) characteristics of commercially available human fibrinogen through a single-dose PK study to provide a basis for the calculation of the dosage of the control drug for acquired fibrinogen deficiency.